Brief: Mink Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
21/03/2023 12:45
March 21 (Reuters) - Mink Therapeutics Inc INKT.O :
* MINK THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS
* MINK THERAPEUTICS INC - AGENT-797 IN COMBINATION WITH
PEMBRO OR
NIVO IN NSCLC AND GASTRIC CANCER TO INITIATE IN 2023
* MINK THERAPEUTICS INC - NET LOSS FOR QUARTER ENDED
DECEMBER 31,
2022, WAS $7.8 MILLION OR $0.23 PER SHARE
Source text for Eikon: ID:nGNX7rgbdJ
Further company coverage: INKT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's